Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Collections
    • Subjects A-Z
    • Residents & Fellows
    • Patient Pages
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

July 01, 2018; 5 (4) Clinical/Scientific NotesOpen Access

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy

Goran Rakocevic, Ubaldo Martinez-Outschoorn and Marinos C. Dalakas
First published April 5, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000460
Goran Rakocevic
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ubaldo Martinez-Outschoorn
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marinos C. Dalakas
From the Department of Neurology (G.R., M.C.D.), Department of Hematology (U.M.-O.), Thomas Jefferson University, Philadelphia, PA; and Neuroimmunology Unit (M.C.D.), Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Greece.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PDF
Citation
Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
Goran Rakocevic, Ubaldo Martinez-Outschoorn, Marinos C. Dalakas
Neurology - Neuroimmunology Neuroinflammation Jul 2018, 5 (4) e460; DOI: 10.1212/NXI.0000000000000460

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Comment

Downloads
0

Share

  • Article
  • Figures & Data
  • Info
Loading

Anti-MAG demyelinating neuropathy is difficult to treat. All immunotherapies have failed except for rituximab, a chimeric B-cell–depleting monoclonal antibody against CD20, that helps up to 40% of patients based on 2 controlled and several uncontrolled series.1,–,3 Because the majority of these patients are left disabled, stronger anti–B-cell agents might be promising.

We describe clinical response and autoantibody changes after treatment with obinutuzumab (Gazyva), a new generation of humanized anti-CD20 monoclonal antibodies, in 2 patients with anti-MAG neuropathy who continued to worsen despite multiple courses of rituximab. Obinutuzumab, approved for chronic lymphocytic leukemia (CLL), exerts greater peripheral and lymphoid B-cell depletion4 and might be more effective in rituximab-refractory patients.

Classification of evidence

This is a single observational study without controls and provides Class IV evidence that obinutuzumab is safe to use in patients with IgM anti-MAG demyelinating neuropathy.

Patients and treatments

Patient 1

A 71-year-old man developed feet paresthesias that progressed in 4 years to bilateral foot drop. Workup revealed distal demyelinating neuropathy, a benign IgMκ monoclonal gammopathy, elevated IgM levels, and high-titer anti-MAG antibodies (table). The gammopathy was benign including normal bone marrow biopsy. He received 3 monthly courses of IVIG without benefits. Rituximab, 2 g, was ineffective without affecting the IgM level or anti-MAG titers while his weakness continued to worsen. Obinutuzumab was then administered in 6 cycles over 6 months, as per the CLL protocol, as follows: day 1: 100 mg; day 2: 900 mg; days 8 and 18: 1,000 mg each; and 1,000 mg thereafter monthly for 5 months.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

IgM levels and anti-MAG antibody titers before and after treatment with obinutuzumab in 2 patients with anti-MAG neuropathy

Patient 2

A 65-year-old man, developed distal leg numbness and paresthesias 13 years ago following successful therapy for colorectal cancer. The neuropathic symptoms gradually worsened with sensory ataxia and muscle weakness. Workup revealed a demyelinating neuropathy, an IgMκ gammopathy, normal bone marrow biopsy, and high-titer anti-MAG antibodies (table). His symptoms transiently improved with oral corticosteroids and IVIG. Over the following 7 years, he received 5 courses of rituximab, 2 g every year. His gait and stamina improved after the first 2 treatments, but there was no further benefit. He gradually progressed with more weakness, requiring MAFOs and canes for ambulation, and prominent hand tremors. The IgMκ spike and high anti-MAG antibody titers persisted. Because of severe disease worsening and continuing disability not responding anymore to rituximab, he was treated with obinutuzumab, administered for 6 months as described above.

Results

There was no clinical improvement or worsening in the patients' neuropathic symptoms 6 and 12 months after treatment with obinutuzumab. In patient 1, the neurologic deficits remained unchanged several months after therapy. Patient 2, 1 year after therapy, showed signs of progression in pace consistent with his pretreatment course; no accelerated worsening related to obinutuzumab was observed. Both patients tolerated the treatment well. Except for transient mild thrombocytopenia, there were no complications during the administration or the follow-up period.

Despite no clinical benefits, however, the IgM levels normalized and remained normal up to a year after obinutuzumab in both patients (table). Of interest, the anti-MAG antibody titers, 6 months after treatments, were also normalized and remained low up to 12 months; the IgMκ spike, however, remained unchanged without discernible differences in the light chain (table). In patient 2, 1 year after obinutuzumab, the anti-MAG titers started to rise, reaching now >70,000 units.

Discussion

The clinical success of first-generation glycoengineered type-I, anti–CD20-mediated, B-cell–depleting, monoclonal antibodies in autoimmune neurologic and rheumatological disorders has provided the rationale for using more potent next-generation anti-CD20 agents. For example, ocrelizumab and ofatumumab seem more effective than rituximab in progressive and relapsing MS.5,6 Obinutuzumab, a third-generation, glycoengineered type-II, humanized anti-CD20 monoclonal antibody approved for CLL, has increased binding affinity to the Fc receptor on B cells and enhanced complement and antibody-dependent cytotoxicity resulting in extensive B-cell lysis of peripheral B cells, including some within the lymphoid tissues; because it also affects IL-6 production, it is expected to cause more sustained depletion of memory B cells and affect antibody production. These effects prompted us to evaluate its efficacy in patients with rituximab-refractory anti-MAG–mediated neuropathy.3 Obinutuzumab, administered for 6 months, was safe but did not improve the patients' symptomatology even up to a year of follow-up. In contrast to rituximab, however, it normalized the IgM level and anti-MAG antibody titers (table). This observation suggests an effect beyond B-cell depletion; B cells play a key role in antigen presentation, complement activation, and cytokine production, such as IL-1, IL-6, and IL-10, that affect immunoregulatory B and T cells and antibody production by plasma cells.7 These preliminary results, even in a limited number of 2 patients, suggest that the IgM anti-MAG antibodies, despite being pathogenic,8 do not seem to correlate with clinical response. Whether this is related to our patients' advanced disease and severe axonal degeneration or to ineffectiveness of obinutuzumab is unclear. The good tolerance of the drug, however, the more profound induction of B-cell depletion, and effect on antibodies, as demonstrated with normalization of IgM and anti-MAG titers, suggest that obinutuzumab might still be considered as an early treatment of this difficult-to-treat neuropathy.

Author contributions

Dr. Rakocevic and Dr. Martinez: study concept and design, acquisition of data, analysis and interpretation, and critical revision of the manuscript for important intellectual content. Dr. Dalakas: study concept and design, analysis and interpretation, critical revision of the manuscript for important intellectual content, and study supervision.

Study funding

No targeted funding reported.

Disclosure

M. Dalakas served on the scientific advisory board of Novartis, Baxalta, and Octapharma; received travel funding and/or speaker honoraria from Merck/Serono, Octapharma, and Pfizer AG; served on the editorial board of/as an editor of Neurology, BMC Neurology, Acta Myologica, Acta Neurologica Scandinavica, and Therapeutic Advances in Neurology; consulted for Therapath, Baxter, Octapharma, CSL, and the Dysimmune Diseases Foundation; received institutional support to Thomas Jefferson University and University of Athens from Merck Serono, Genzyme, Novartis, the Guillain-Barré Syndrome/CIDP Foundation, Dysimmune Diseases Foundation, CSL, Biogen, and Newfactor; G. Rakocevic reports no disclosures. U. Martinez-Outschoorn served on the editorial board of the American Journal of Pathology; received research support from Otsuka Pharmaceuticals and the NIH/NCI. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

  • The Article Processing Charge was funded by the authors.

  • Received January 8, 2018.
  • Accepted in final form March 5, 2018.
  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Dalakas MC,
    2. Rakocevic G,
    3. Salajegheh M, et al
    . Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65:286–293.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Ferfoglia R,
    2. Guimarães-Costa R,
    3. Viala K, et al
    . Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst 2016;21:10–14.
    OpenUrl
  3. 3.↵
    1. Dalakas MC
    . Rituximab an anti-MAG neuropathy: more evidence for efficacy and more predictive factors. J Neurol Sci 2017;377:224–226.
    OpenUrl
  4. 4.↵
    1. Dalakas MC
    . B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;4:557–567.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Montalban X,
    2. Hauser SL,
    3. Kappos L, et al
    . Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209–220.
    OpenUrlCrossRef
  6. 6.↵
    1. Bar-Or A,
    2. Grove R,
    3. Austin D, et al
    . The MIRROR Study: a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and MRI efficacy of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis. Neurology 2014;82:S23.006.
    OpenUrl
  7. 7.↵
    1. Li R,
    2. Rezk A,
    3. Healy LM, et al
    . Cytokine-defined B cell responses as therapeutic targets in multiple sclerosis. Front Immunol 2015;6:626.
    OpenUrlPubMed
  8. 8.↵
    1. Latov N
    . Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995;37:S32–S42.
    OpenUrlCrossRefPubMed
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
Publication Date - String

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Classification of evidence
    • Patients and treatments
    • Results
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Figures & Data
  • Info

Related Articles

  • No related articles found.

Topics Discussed

  • All Immunology
  • Autoimmune diseases
  • Class IV
  • Peripheral neuropathy

Alert Me

  • Alert me when this article is cited
  • Alert me if a correction is posted
  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 5 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Submit a Peer Review
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2018 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise